Inactive Instrument

News Endologix, Inc. Nasdaq

Stocks

US29266S1069

Medical Equipment, Supplies & Distribution

All News

07-02	Endologix Publishes 36-Month Results from the Detour2 Clinical Trial Evaluating the Detour System	CI
05-18	Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc.	CI
05-07	Endologix LLC Announces Appointment of Steve Deitsch to Board of Directors	CI
25-07-09	Endologix Announces That Scott Huennekens Joins Board of Directors	CI
25-03-20	Endologix Announces 1000 Patients Treated with the Detour? System	CI
25-03-03	Endologix LLC Appoints Andrew Davis as Chief Commercial Officer	CI
25-01-07	Endologix LLC Announces Chief Executive Officer Changes	CI
25-01-07	Endologix LLC Announces Executive Changes	CI
24-11-05	Endologix LLC Announces 36-Month Results of Detour2 Study At 2024 Viva Late-Breaking Clinical Trial Session	CI
24-06-18	Endologix LLC Appoints Graham Phillips as Chief Operating Officer	CI
24-05-13	Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery	CI
24-03-05	Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	CI
24-01-25	Endologix LLC Announces That Art Taylor Joins Board of Directors	CI
24-01-09	Endologix LLC Appoints Scott Ward Joins Board of Directors	CI
24-01-09	Endologix LLC Announces Appointment of Scott Ward as Board of Directors	CI
23-12-27	Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	CI
23-11-02	Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	CI
23-09-07	Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	CI
23-08-24	Endologix LLC Appoints Lucas Buchanan to its Board of Directors	CI
23-07-18	Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	CI
23-06-15	Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	CI
23-06-08	Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	CI
23-05-23	Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	CI
22-11-11	Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	CI
22-11-03	Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	CI